RESULTS FROM THE PHASE 1 DOSE ESCALATION STUDY OF XMT-1592, A DOLASYNTHEN NAPI2B-DIRECTED ANTIBODY-DRUG CONJUGATE (ADC)

Authors
Category Primary study
JournalInt. J. Gynecol. Cancer
Year 2024
This article has no abstract
Epistemonikos ID: 465d4d15b09d56325fc59d83d7de8d2119cda7e3
First added on: Mar 08, 2025